BNP Paribas Financial Markets
NGNE icon

BNP Paribas Financial Markets’s Neurogene NGNE Stock Holding History

BNP Paribas Financial Markets’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.7K Sell
1,898
-796
-30% -$21.9K ﹤0.01% 4801
2026
Q1 		$54.3K Buy
2,694
+270
+11% +$5.23K ﹤0.01% 4651
2025
Q4 		$49.9K Buy
2,424
+357
+17% +$8.89K ﹤0.01% 4685
2025
Q3 		$35.8K Buy
2,067
+978
+90% +$19.6K ﹤0.01% 4730
2025
Q2 		$16.3K Buy
1,089
+260
+31% +$4.08K ﹤0.01% 4691
2025
Q1 		$9.71K Sell
829
-551
-40% -$9.57K ﹤0.01% 4722
2024
Q4 		$31.5K Sell
1,380
-790
-36% -$29.4K ﹤0.01% 4589
2024
Q3 		$91.1K Buy
2,170
+1,429
+193% +$55.4K ﹤0.01% 3487
2024
Q2 		$27K Buy
+741
New +$26.1K ﹤0.01% 3598

Other funds holding NGNE

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BNP Paribas Financial Markets's NGNE Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Neurogene (NGNE) stake by 30% in Q2 2026, selling an estimated $21.9K and leaving 1,898 shares worth $59.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4801.

BNP Paribas Financial Markets first reported a position in NGNE in Q2 2024 and has held it in 9 quarters since. The position peaked at $91.1K in Q3 2024. 102 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • BNP Paribas Financial Markets held 1,898 shares of Neurogene worth $59.7K as of Q2 2026.
  • BNP Paribas Financial Markets sold 796 Neurogene shares in Q2 2026, an estimated $21.9K.
  • Neurogene made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4801 holding.
  • BNP Paribas Financial Markets first reported a position in Neurogene in Q2 2024 and has held it in 9 quarters since.
  • BNP Paribas Financial Markets's Neurogene position peaked at $91.1K in Q3 2024.
  • 102 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.